Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C.
about
Antiviral therapies for chronic hepatitis C virus infection with cirrhosisIdentification of a novel drug lead that inhibits HCV infection and cell-to-cell transmission by targeting the HCV E2 glycoproteinManagement of hepatitis C infection before and after liver transplantationSafety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET.Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy.Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemiaEffectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosisPrediction of Sustained Virological Response to Telaprevir-Based Triple Therapy Using Viral Response within 2 Weeks.Limited utility of ITPA deficiency to predict early anemia in HCV patients with advanced fibrosis receiving Telaprevir.First-generation protease inhibitor-triple therapy: SVR 24, safety, and predictors of response in a large single center cohortPredicting the impact of adverse events and treatment duration on medical resource utilization-related costs in hepatitis C genotype 1 treatment-naïve patients receiving antiviral therapy.Hepatitis C treatment in the elderly: New possibilities and controversies towards interferon-free regimens.Final Results of the Telaprevir Access Program: FibroScan Values Predict Safety and Efficacy in Hepatitis C Patients with Advanced Fibrosis or Cirrhosis.Effect of Peginterferon or Ribavirin Dosing on Efficacy of Therapy With Telaprevir in Treatment-Experienced Patients With Chronic Hepatitis C and Advanced Liver Fibrosis: A Multicenter Cohort Study.Determinant Factors of the Direct Medical Costs Associated with Genotype 1 Hepatitis C Infection in Treatment-Experienced Patients.Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in KoreaTelaprevir- and Boceprevir-based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease: A Multicenter Study.Predictors of early treatment discontinuation and severe anemia in a Brazilian cohort of hepatitis C patients treated with first-generation protease inhibitors.Optimizing choice of oral interferon-free treatment for genotype 1 hepatitis C virus using testing for NS5A resistance: a cost-utility analysis from the perspective of the Italian National Health Service.Treating hepatitis C in the elderly: the future is near?Optimal management of patients with chronic hepatitis C and comorbidities.Review article: the efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection.Development of antiviral drugs for the treatment of hepatitis C at an accelerating pace.Protease inhibitors-based therapy induces acquired spherocytic-like anaemia and ineffective erythropoiesis in chronic hepatitis C virus patients.Daclatasvir: a team player rather than a prima donna in the treatment of hepatitis C.[Health-Related Quality of Life in patients with hepatitis C treated with dual and triple therapy].
P2860
Q27022794-7E7EF3E7-576A-4183-9FDA-F329C7F5D5B2Q27333881-0AB7191B-65D0-4842-AB5B-158E0A8BB11AQ28081250-C12A9D02-B8E3-494D-AA79-A185AB0F1B3FQ30361098-83250C88-175D-4EAB-A16D-4E5BC72B4C4EQ33422417-2F03E569-9FC1-4E98-8ED6-BD8561E3E4DDQ33424963-28D1CB96-0232-4822-82A4-F5E4E040C139Q33425278-2FA50F0B-97B5-4A1C-A443-E5E10183C3C6Q34330704-CAC45E91-4D10-4991-8132-3E77F7BCC048Q35156156-318449B9-FB51-4014-918F-0F47319B36E3Q35164782-CAB93677-9715-4ACF-B04E-2F9120341E26Q35237179-2649313A-3AF4-4206-A671-D553AFC68A20Q35783876-ED67D69B-874B-4E55-AF19-5FC960E2D806Q35785198-A84AB5BD-1B07-49B3-8DC6-45143FD4F644Q36255875-F0C9D6FF-28DB-46DD-A495-944F100A79C5Q36327795-764A7027-7983-4BCA-A104-579BA27D8226Q36460249-1F0BD502-26DF-43AA-A3AF-102140F4A4EBQ36760075-D0EB5F2F-F119-49F0-A6DE-CF01D7671E1EQ37050953-B4A42C82-846A-45FC-89D2-8970D44FE430Q37682673-E226E6C3-C013-4EB6-8F9F-7AF0CDFE5A56Q38243001-F1E47DF4-F109-42C8-B699-F4C8559CA46CQ38295819-D22D95BB-B32D-48A5-97C8-8457B00EEF8AQ38503778-C9D5A5B3-AB10-49DB-8754-427201D0D78EQ38515906-B6D2DEDF-2732-4C94-9B1C-2CF9B062F417Q41143424-C1A12AAC-1731-41D1-A584-12B7E81F6985Q42192444-7F181AA5-EBDB-4CAF-B1B8-80A19624A3B7Q50270442-A887BC26-EC6B-479E-A45B-405211742748
P2860
Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C.
description
2013 nî lūn-bûn
@nan
2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Safety and on-treatment effica ...... nts with advanced hepatitis C.
@ast
Safety and on-treatment effica ...... nts with advanced hepatitis C.
@en
type
label
Safety and on-treatment effica ...... nts with advanced hepatitis C.
@ast
Safety and on-treatment effica ...... nts with advanced hepatitis C.
@en
prefLabel
Safety and on-treatment effica ...... nts with advanced hepatitis C.
@ast
Safety and on-treatment effica ...... nts with advanced hepatitis C.
@en
P2093
P2860
P1433
P1476
Safety and on-treatment effica ...... ents with advanced hepatitis C
@en
P2093
A Verheyen
D Abdurakhmanov
H Wedemeyer
I Fernández
I Lonjon-Domanec
J M Läuffer
P A Ferreira
P2860
P304
P356
10.1136/GUTJNL-2013-305667
P407
P577
2013-11-07T00:00:00Z